Search Result

Results for "

HLA-A2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) EGFR (1) HCV (1) HPV (3) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cancer (8) Infection (2) Inflammation/Immunology (3)
Oligonucleotides:	Pre-designed siRNA Sets (2) siRNAs (2)

Inhibitors & Agonists

Peptides

Oligonucleotides

Targets Recommended: CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1778A

HPV16 E7 (86-93) (TFA)	HPV	Infection
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas ^[2].

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2* in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P1778

HPV16 E7 (86-93)	HPV	Infection
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas ^[2].

HY-RS06206

HLA-DQA2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQA2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQA2 Human Pre-designed siRNA Set A HLA-DQA2 Human Pre-designed siRNA Set A

HY-RS06208

HLA-DQB2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-DQB2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQB2 Human Pre-designed siRNA Set A HLA-DQB2 Human Pre-designed siRNA Set A

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to *HLA-DR2*. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1778A

HPV16 E7 (86-93) (TFA)	HPV	Infection
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas ^[2].

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P1700

BCMA72-80	Peptides	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P10493

NY-ESO-1 (157–165) peptide	Peptides	Others Cancer
NY-ESO-1 (157–165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157–165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157–165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy. NY-ESO-1 (157–165) peptide can be used in the study of cancer immunotherapy .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2* in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P2524

MAGE-3 (271-279)	Peptides	Cancer
MAGE-3 (271-279) is a 271-279 residue peptide derived from melanoma antigens encoded by MAGE-3. MAGE-3 is a cytolytic T lymphocyte (CTL)-defined MAGE-3 protein associated with the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is overexpressed in different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta .

HY-106187

MART-1 (27-35) (human)	Peptides	Inflammation/Immunology
MART-1 (27-35) (human) is an immunogenic epitope recognized by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TIL) .

HY-P1778

HPV16 E7 (86-93)	HPV	Infection
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas ^[2].

HY-P5294

YLLEMLWRL	Peptides	Cancer
YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .

HY-P1919

[Asp371]-Tyrosinase (369-377), human	Peptides	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy ^[2].

HY-P1914

NY-BR-1 p904 (A2)	Peptides	Cancer
NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1 .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-P3248

J5 peptide Myelin basic protein (85-99) antagonist	Biochemical Assay Reagents	Inflammation/Immunology
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP_85-99 to *HLA-DR2*. J5 peptide alleviates PLP_139-151/MBP_85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .

HLA-DQA2 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
HLA-DQA2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-DQB2 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
HLA-DQB2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.